No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

byTeddy Guo

January 14, 2021

in StudyGraphics

Reading Time: 1 min read

COVID-19 associated with significant mental health issues among college students in America

RelatedReports

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors

Chronic Disease

Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer

November 21, 2024

StudyGraphics

#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

October 18, 2024

StudyGraphics

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

September 27, 2024

Adding sargramostim to ipilimumab may improve survival in advanced melanoma

Pharma

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

September 3, 2024

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer

#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

COVID-19 associated with significant mental health issues among college students in America

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

RelatedReports

Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer

#VisualAbtract: Durvalumab After Chemoradiotherapy Increased Survival in Limited-Stage Small-Cell Lung Cancer

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written
medical news?

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

RELATED REPORTS

COVID-19 associated with significant mental health issues among college students in America

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written medical news?

Want more physician-written
medical news?